Gilead Sciences (GILD) upgraded to Buy by Truist after raising its 2023 sales outlook. Read more here.

Pharma Amid excitement over Yeztugo, Gilead sees continued erosion of CAR-T sales By Kevin Dunleavy Aug 8, 2025 11:40am Gilead Sciences Yescarta (axicabtagene ciloleucel) Tecartus CAR-T ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year outlook.

Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.9 billion Biktarvy Sales Increased 9% Year-Over-Year to $3.5 billion FOSTER CITY, Calif.-- (BUSINESS WIRE)-- #Earnings --Gilead ...

The bottom line: We're raising our fair value estimate to $115 from $108 for wide-moat Gilead, as management's initial demand and coverage commentary for Yeztugo has led us to raise our long-term ...

Fintel reports that on August 8, 2025, Truist Securities upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold to Buy. Analyst Price Forecast Suggests 9.43% Upside As of August 5 ...

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV PrEP Yeztugo—that insurers must cover. A recently postponed meeting has raised ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the establishment of a Commission comprising a wide range of medical and ...

NEW YORK – Sales of Gilead's two cell therapies tempered its overall results in the second quarter of 2025, but the company said recent rollbacks of CAR T-cell safety monitoring regulations could help ...

Gilead Sciences GILD-0.93%decrease; red down pointing triangle raised its guidance for the year after posting better-than-expected results in the second quarter, driven by higher sales from ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced earnings for its second quarter that Increased from the same period last year and beat the Street estimates.